Recursion Pharma Files 8-K on Financial Results and Disclosures

Ticker: RXRX · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1601830

Recursion Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRecursion Pharmaceuticals, Inc. (RXRX)
Form Type8-K
Filed DateFeb 27, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-results, regulation-fd, corporate-filing

Related Tickers: RXRX

TL;DR

**Recursion Pharma just dropped an 8-K on financial results and disclosures, stay tuned for details!**

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, reporting on its results of operations and financial condition. The filing also included Regulation FD Disclosure and financial statements and exhibits. This current report, filed under the Securities Exchange Act of 1934, details events that occurred on February 27, 2024, from their principal executive offices at 41 S Rio Grande Street, Salt Lake City, UT.

Why It Matters

This filing provides transparency into Recursion Pharmaceuticals' financial health and operational performance, offering investors and the public crucial information for decision-making.

Risk Assessment

Risk Level: medium — An 8-K reporting financial results can contain significant news, positive or negative, impacting the company's stock price.

Key Players & Entities

  • RECURSION PHARMACEUTICALS, INC. (company) — registrant
  • Delaware (company) — state of incorporation
  • Salt Lake City (company) — business location
  • February 27, 2024 (date) — date of earliest event reported
  • 001-40323 (other) — Commission File Number

FAQ

What is the purpose of this 8-K filing by Recursion Pharmaceuticals, Inc.?

This 8-K filing reports on the company's results of operations and financial condition, includes Regulation FD Disclosure, and provides financial statements and exhibits, as indicated by the 'ITEM INFORMATION' sections.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 27, 2024.

What is the full legal name of the registrant company?

The exact name of the registrant as specified in its charter is Recursion Pharmaceuticals, Inc.

Where are Recursion Pharmaceuticals, Inc.'s principal executive offices located?

The principal executive offices of Recursion Pharmaceuticals, Inc. are located at 41 S Rio Grande Street, Salt Lake City, UT 84101.

What is the Commission File Number for Recursion Pharmaceuticals, Inc.?

The Commission File Number for Recursion Pharmaceuticals, Inc. is 001-40323.

Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-02-27 16:09:07

Key Financial Figures

  • $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 27, 2024, Recursion Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On February 27, 2024, the Company released an updated investor presentation. The investor presentation will be used from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.2. Also on February 27, 2024, the Company released a presentation made in connection with its L(earnings) call on February 27, 2024. A copy of the presentation is attached hereto as Exhibit 99.3. The Company announces material information to its investors using filings with the Securities and Exchange Commission (the "SEC"), the investor relations page on the Company's website, at https://ir.recursion.com/, press releases, public conference calls and webcasts. The Company uses these channels, as well as social media, to communicate with investors and the public about the Company, its products and services and other matters. Therefore, the Company encourages investors, the media and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information. The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and 7.01 (including Exhibits 99.2 and 99.3) on this Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release issued by Recursion Pharmaceuticals, Inc. dated February 27, 202 4 99.2 Investor presentation of Recursion Pharmaceuticals, Inc. dated February 27, 2024 99.3 L(earnings) call presentation of Recursion Pharmaceuticals, Inc. dated February 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on February 27, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Michael Secora Michael Secora Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.